The global cell dissociation solution market size was valued at USD 294.9 million in 2022. The market is projected to grow from USD 294.9 million in 2022 to USD 872.8 million by 2030, exhibiting a CAGR of 14.90% during the forecast period.
The rising demand for RD in biopharmaceutical businesses is one of the key factors anticipated to propel the growth of the cell dissociation market during the forecast period. Additionally, it is projected that the favourable funding environment for cancer research and the rising incidence and prevalence of infectious and chronic diseases will fuel the expansion of the cell dissociation market. Furthermore, the rising attention on customised treatment and increase in the government funding for cell-based research is further expected to cushion the growth of the cell dissociation market. On the other hand, it is anticipated that the development of the cell dissociation market will be hampered further by the rising expense of cell-based research and the lack of infrastructure for cell-based research in the developing nations.
Read Comprehensive Overview of Report @ https://marketsnresearch.com/report/1660/global-cell-dissociation-solution-market
Major Players Develop Acquisition Plans to Boost Brand Image
The leading businesses in the cell dissociation solution market plan acquisitions to improve their brand recognition globally. For instance, in 2021, a definitive merger agreement between Roche Diagnostics and GenMark Diagnostics was signed in order to have access to cutting-edge technologies for testing several infections in a single patient sample.
- In September 2022, Thermo Fisher unveiled the Orbitrap Ascend TriBrid last month at the International Mass Spectrometry Conference in Maastricht, Netherlands. This premium equipment is intended for proteomic and biopharma applications.
Read More News :
